Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SZSE:301093's ROA % is ranked better than 53.46% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 0.74
vs SZSE:301093: 1.68
Jiangsu Hualan New Pharmaceutical Material Co (SZSE:301093) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Jiangsu Hualan New Pharmaceutical Material Co ROA % Related Terms
Jiangsu Hualan New Pharmaceutical Material Co ROA % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Hualan New Pharmaceutical Material Co ROA % Chart
Jiangsu Hualan New Pharmaceutical Material Co Annual Data
For the Medical Instruments & Supplies subindustry, Jiangsu Hualan New Pharmaceutical Material Co's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangsu Hualan New Pharmaceutical Material Co ROA % vs Medical Devices & Instruments Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Jiangsu Hualan New Pharmaceutical Material Co (SZSE:301093) has a ROA % of 0.10% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Jiangsu Hualan New Pharmaceutical Material Co and its competitors. This is 99% below median its historical median of 13.27. Over the past decade, Jiangsu Hualan New Pharmaceutical Material Co's ROA % has ranged from 1.68 to 16.43. According to the industry distribution chart, Jiangsu Hualan New Pharmaceutical Material Co ranks #397 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 46.5%.
Is Jiangsu Hualan New Pharmaceutical Material Co's ROA % too high?
Jiangsu Hualan New Pharmaceutical Material Co's current ROA % of 0.10% is 99% below median its 10-year median of 13.27. Over the past 10 years, this metric has ranged from a low of 1.68 to a high of 16.43. The Medical Devices & Instruments industry median ROA % is 0.74. Jiangsu Hualan New Pharmaceutical Material Co's value of 0.10% is 86.5% below this industry median. Based on the distribution chart, Jiangsu Hualan New Pharmaceutical Material Co ranks #397 out of 853 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Jiangsu Hualan New Pharmaceutical Material Co has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Hualan New Pharmaceutical Material Co's ROA % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Jiangsu Hualan New Pharmaceutical Material Co ranks #397 out of 853 companies for ROA %. This puts Jiangsu Hualan New Pharmaceutical Material Co in the upper half of its industry. The industry median ROA % is 0.74. Jiangsu Hualan New Pharmaceutical Material Co's value of 0.10% is 86.5% below this benchmark. Historically, Jiangsu Hualan New Pharmaceutical Material Co's own ROA % has ranged from 1.68 to 16.43 over the past decade. While the company's 10-year median is 13.27 vs. the industry median of 0.74, Jiangsu Hualan New Pharmaceutical Material Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Devices & Instruments company?
The median ROA % among Medical Devices & Instruments companies is 0.74, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangsu Hualan New Pharmaceutical Material Co's current ROA % of 0.10% is 86.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Jiangsu Hualan New Pharmaceutical Material Co and its competitors. For the Medical Devices & Instruments industry, the median ROA % is 0.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangsu Hualan New Pharmaceutical Material Co's current ROA % is 0.10%, which is 99% below median its own 10-year median of 13.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Hualan New Pharmaceutical Material Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Hualan New Pharmaceutical Material Co (SZSE:301093) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥23.79, compared to a current price of ¥74.73 — trading 214.1% above its estimated fair value. The current ROA % is 0.10%, which is 99% below median its 10-year median of 13.27 and 86.5% below the Medical Devices & Instruments industry median of 0.74. Jiangsu Hualan New Pharmaceutical Material Co's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Jiangsu Hualan New Pharmaceutical Material Co (SZSE:301093), the current ROA % is 0.10% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jiangsu Hualan New Pharmaceutical Material Co (SZSE:301093) Overvalued in 2026?
Based on GuruFocus' analysis, Jiangsu Hualan New Pharmaceutical Material Co stock appears to be overvalued.
The current stock price of ¥74.73 is trading 214.1% above its estimated GF Value™ of ¥23.79.
GuruFocus considers Jiangsu Hualan New Pharmaceutical Material Co to be Significantly Overvalued.
Key valuation signals for SZSE:301093:
ROA %: 0.10% (99% below median its 10-year median of 13.27)
GF Value™: ¥23.79 vs. price of ¥74.73 (214.1% above fair value)
Industry Position: 86.5% below the Medical Devices & Instruments median (#397 of 853)
No single metric tells the full story. See the SZSE:301093 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jiangsu Hualan New Pharmaceutical Material Co Ltd is engaged in direct contact with the research and development, production and sales of packaging materials for injection drugs. The company's main products are medicinal sealing elastomers such as film-coated rubber plugs for high and middle end injections, conventional rubber plugs, pre-filled pistons, and silicone seals.
69GF Score
Get the complete analysis for SZSE:301093
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:301093 has been successfully added to your 
